Viatris’ Mylan And Apotex Lose Again Over US Bendeka Patents
ANDA Sponsors Continue To Be Barred From Launch Until 2031
Viatris’ Mylan and Apotex once again fell to Teva and Eagle Pharmaceuticals in their battle to introduce generic versions of the rapid-infusion bendamustine formulation, Bendeka, with the US Federal Circuit upholding a lower court judgement.
You may also be interested in...
In a busy final month of the year, key legal action will be heard in both the US and Europe, while the Medicines Patent Pool will hear from applicants for a milestone voluntary licensing agreement covering Novartis’ nilotinib.
In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.
Court orders US FDA to award Bendeka seven years of exclusivity without requiring clinical superiority test; law codifying FDA policy passed prior to suit and is not retroactive.